309 related articles for article (PubMed ID: 31143074)
1. Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease.
Gong SS; Fan YH; Han QQ; Lv B; Xu Y
World J Gastroenterol; 2019 May; 25(18):2240-2250. PubMed ID: 31143074
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for opportunistic infections in patients with inflammatory bowel disease.
Toruner M; Loftus EV; Harmsen WS; Zinsmeister AR; Orenstein R; Sandborn WJ; Colombel JF; Egan LJ
Gastroenterology; 2008 Apr; 134(4):929-36. PubMed ID: 18294633
[TBL] [Abstract][Full Text] [Related]
3. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease.
Naganuma M; Kunisaki R; Yoshimura N; Takeuchi Y; Watanabe M
J Gastroenterol; 2013 May; 48(5):595-600. PubMed ID: 23053426
[TBL] [Abstract][Full Text] [Related]
4. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
Kirchgesner J; Lemaitre M; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
Gastroenterology; 2018 Aug; 155(2):337-346.e10. PubMed ID: 29655835
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF containing regimens may be associated with increased risk of Clostridioides difficile infection in patients with underlying inflammatory bowel disease.
Gholam-Mostafaei FS; Yadegar A; Aghdaei HA; Azimirad M; Daryani NE; Zali MR
Curr Res Transl Med; 2020 Aug; 68(3):125-130. PubMed ID: 32414632
[TBL] [Abstract][Full Text] [Related]
6. Risk factors and clinical outcome of Clostridium difficile infection in patients with IBD: A single-center retrospective study of 260 cases in China.
Gu YB; Zhang MC; Sun J; Lv KZ; Zhong J
J Dig Dis; 2017 Apr; 18(4):207-211. PubMed ID: 28251812
[TBL] [Abstract][Full Text] [Related]
7. Opportunistic Infection in Hospitalised Patients with Inflammatory Bowel Disease.
Zhou JQ; Meng ZM; Zhang T; Jing XT; Gan HT
J Coll Physicians Surg Pak; 2020 Oct; 30(10):1015-1020. PubMed ID: 33143819
[TBL] [Abstract][Full Text] [Related]
8. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.
Loras C; Gisbert JP; Mínguez M; Merino O; Bujanda L; Saro C; Domenech E; Barrio J; Andreu M; Ordás I; Vida L; Bastida G; González-Huix F; Piqueras M; Ginard D; Calvet X; Gutiérrez A; Abad A; Torres M; Panés J; Chaparro M; Pascual I; Rodriguez-Carballeira M; Fernández-Bañares F; Viver JM; Esteve M; ;
Gut; 2010 Oct; 59(10):1340-6. PubMed ID: 20577000
[TBL] [Abstract][Full Text] [Related]
9. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis.
Klingberg E; Strid H; Ståhl A; Deminger A; Carlsten H; Öhman L; Forsblad-d'Elia H
Arthritis Res Ther; 2017 Feb; 19(1):21. PubMed ID: 28148281
[TBL] [Abstract][Full Text] [Related]
10. Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary.
Veereman-Wauters G; de Ridder L; Veres G; Kolacek S; Fell J; Malmborg P; Koletzko S; Dias JA; Misak Z; Rahier JF; Escher JC;
J Pediatr Gastroenterol Nutr; 2012 Jun; 54(6):830-7. PubMed ID: 22584748
[TBL] [Abstract][Full Text] [Related]
11. Individualized Infliximab Treatment Guided by Patient-managed eHealth in Children and Adolescents with Inflammatory Bowel Disease.
Carlsen K; Houen G; Jakobsen C; Kallemose T; Paerregaard A; Riis LB; Munkholm P; Wewer V
Inflamm Bowel Dis; 2017 Sep; 23(9):1473-1482. PubMed ID: 28617758
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus in inflammatory bowel disease-correlation with different therapeutic regimens.
Magro F; Santos-Antunes J; Albuquerque A; Vilas-Boas F; Macedo GN; Nazareth N; Lopes S; Sobrinho-Simões J; Teixeira S; Dias CC; Cabral J; Sarmento A; Macedo G
Inflamm Bowel Dis; 2013 Jul; 19(8):1710-6. PubMed ID: 23574759
[TBL] [Abstract][Full Text] [Related]
13. Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines.
Wisniewski A; Kirchgesner J; Seksik P; Landman C; Bourrier A; Nion-Larmurier I; Marteau P; Cosnes J; Sokol H; Beaugerie L;
United European Gastroenterol J; 2020 Apr; 8(3):303-313. PubMed ID: 32529821
[TBL] [Abstract][Full Text] [Related]
14. Case-Control Study of Inflammatory Bowel Disease Patients with and without Clostridium difficile Infection and Poor Outcomes in Patients Coinfected with C. difficile and Cytomegalovirus.
Li Y; Xu H; Xu T; Xiao M; Tang H; Wu D; Tan B; Li J; Yang H; Lv H; Xu Y; Qian J
Dig Dis Sci; 2018 Nov; 63(11):3074-3083. PubMed ID: 30094621
[TBL] [Abstract][Full Text] [Related]
15. EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
Pedersen N
Dan Med J; 2015 Dec; 62(12):B5168. PubMed ID: 26621403
[TBL] [Abstract][Full Text] [Related]
16. Success and safety of high infliximab trough levels in inflammatory bowel disease.
Drobne D; Kurent T; Golob S; Svegl P; Rajar P; Terzic S; Kozelj M; Novak G; Smrekar N; Plut S; Sever N; Strnisa L; Hanzel J; Brecelj J; Urlep D; Osredkar J; Homan M; Orel R; Stabuc B; Ferkolj I; Smid A
Scand J Gastroenterol; 2018 Aug; 53(8):940-946. PubMed ID: 29987967
[TBL] [Abstract][Full Text] [Related]
17. Infection-related hospitalizations in the first year after inflammatory bowel disease diagnosis.
Ko MK; Ng SC; Mak LY; Li MK; Lo FH; Ng CK; Lao WC; Tsang S; Chan KH; Hui YT; Shan EH; Loo CK; Hui AJ; To WP; Hung IF; Leung WK
J Dig Dis; 2016 Sep; 17(9):610-617. PubMed ID: 27533786
[TBL] [Abstract][Full Text] [Related]
18. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.
Roblin X; Boschetti G; Duru G; Williet N; Deltedesco E; Phelip JM; Peyrin-Biroulet L; Nancey S; Flourié B; Paul S
Inflamm Bowel Dis; 2017 Nov; 23(11):2048-2053. PubMed ID: 28945636
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease.
Vögelin M; Biedermann L; Frei P; Vavricka SR; Scharl S; Zeitz J; Sulz MC; Fried M; Rogler G; Scharl M
PLoS One; 2016; 11(5):e0155218. PubMed ID: 27214202
[TBL] [Abstract][Full Text] [Related]
20. Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease.
Lee JM; Kim YJ; Lee KM; Yoon H; Lee BI; Kim DB; Kang D
Scand J Gastroenterol; 2018; 53(10-11):1280-1285. PubMed ID: 30351977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
